
American College of Obstetricians and Gynecologists v. U.S. Food and Drug Administration
What's at Stake
The American Civil Liberties Union filed a federal lawsuit challenging an FDA rule that subjects patients to unnecessary risks of contracting COVID-19 as a condition of receiving a medication used for early abortion and miscarriage treatment.
Stay informed about our latest work in the courts.
By completing this form, I agree to receive occasional emails per the terms of the ACLU's privacy statement.
Summary
Mifepristone is a drug used to safely and effectively end early pregnancies and treat early miscarriage. For more than 20 years, people in the United States have used mifepristone, in combination with another drug, misoprostol, to end an early pregnancy. The FDA, however, has long subjected mifepristone, when used for pregnancy termination, to a set of unnecessary requirements that make it more difficult for patients to access care.
During the COVID-19 pandemic, the FDA has continued to enforce those requirements, including one in particular — the in-person dispensing requirement — that puts patients’ health and lives at risk as a condition of obtaining abortion and miscarriage care. Patients are forced to make an unnecessary trip to a hospital, clinic, or medical office to pick up the mifepristone pill—even when they will be receiving no in-person medical services at that time and will swallow the pill later at home (as the FDA permits). Out of more than 20,000 FDA-approved drugs, mifepristone is the only drug that the FDA requires to be dispensed only in clinical settings while permitting patients to self-administer it at home. The FDA permits patients taking mifepristone for reasons other than pregnancy termination to receive the drug through the mail in much higher doses and quantities.
By continuing to enforce the In-Person Dispensing Requirement during the pandemic, the FDA unnecessarily exposes patients and clinicians to heightened COVID-19 risks, jeopardizing their health and lives for no medical purpose. These unjustified risks are magnified for low-income people and people of color, who comprise a majority of impacted patients, and who are already suffering outsized rates of severe illness and fatality from COVID-19.
The case was filed in the U.S. District Court in the District of Maryland on behalf of the American College of Obstetricians & Gynecologists, the Council of University Chairs of Obstetrics and Gynecology, New York State Academy of Family Physicians, SisterSong Women of Color Reproductive Justice Collective, and an individual family medicine doctor.
Legal Documents
- 12/23/2020
Plaintiffs’ Response in Opposition
- 12/09/2020
U.S. District Court for the District of Maryland Ruling
Date Filed: 12/09/2020
Affiliate: Maryland
Download Document- 12/08/2020
Dr. Sarpatwari Physician Declaration
- 12/08/2020
Dr. MacNaughton Physician Declaration
- 12/04/2020
Dr. Paladine Physician Declaration
- 12/04/2020
Dr. Chen Physician Declaration
- 12/04/2020
Dr. Floyd Physician Declaration
- 12/04/2020
Dr. Espey Physician Declaration
- 10/08/2020
Supreme Court Order on Application For Stay
- 07/13/2020
Preliminary Injunction Granted
- 01/12/2021
Supreme Court Order Granting Stay
Press Releases
ACLU Statement on FDA Suspension of Restrictions on Medication Abortion
Leading Medical Organizations, Members of Congress, State Attorneys General Join Challenge to FDA Restrictions on Medication Abortion
Supreme Court Grants Trump Administration Request to Endanger Abortion Patients During the Pandemic
ACLU Response to Second Trump Administration Petition to Supreme Court on Medication Abortion Access During the Pandemic
Federal Court Upholds ACLU Victory, Blocks Policy That Exposes Abortion Patients to Unnecessary COVID-19 Risk
Supreme Court Delays Decision in Abortion Case Until After Election